When it comes to NVDA… “acceleration cycles” are the key

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

Jeffrey Moy Biography and Net Worth

EVP of DexCom

Jeffrey C. Moy serves as Senior Vice President - Operations of the Company. He has served as our Senior Vice President of Operations since January 2011 and was promoted to Executive Vice President, Operations, effective October 1, 2019. He previously served as our Vice President of Operations from September 2008 to January 2011. Previously, Mr. Moy served as our Senior Director of Manufacturing from September 2007 to September 2008. From April 2004 to August 2007, Mr. Moy served as Senior Director of Manufacturing for Biosite, Inc., a manufacturer of diagnostic products for point of care medicine. Mr. Moy received a B.S. from the University of Pennsylvania and a Masters in Engineering from Cornell University.

What is Jeffrey Moy's net worth?: The estimated net worth of Jeffrey Moy is at least $2.26 million as of March 2nd, 2020. Mr. Moy owns 30,408 shares of DexCom stock worth more than $2,264,180 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Moy may own. Learn More about Jeffrey Moy's net worth.
How do I contact Jeffrey Moy?: The corporate mailing address for Mr. Moy and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Jeffrey Moy's contact information.
Has Jeffrey Moy been buying or selling shares of DexCom?: Jeffrey Moy has not been actively trading shares of DexCom over the course of the past ninety days. Most recently, Jeffrey Moy sold 362 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $278.10, for a transaction totalling $100,672.20. Following the completion of the sale, the executive vice president now directly owns 30,408 shares of the company's stock, valued at $8,456,464.80. Learn More on Jeffrey Moy's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 28 times. They sold a total of 252,409 shares worth more than $33,128,636.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 9/9/2024.

Jeffrey Moy Insider Trading History at DexCom

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/2/2020	Sell	362	$278.10	$100,672.20	30,408
2/18/2020	Sell	6,599	$286.91	$1,893,319.09
9/9/2019	Sell	4,601	$149.85	$689,459.85
8/1/2018	Sell	5,831	$94.13	$548,872.03	68,511
6/28/2018	Sell	59,193	$92.48	$5,474,168.64	68,511
8/1/2016	Sell	15,000	$92.33	$1,384,950.00	107,582
7/22/2016	Sell	10,000	$88.48	$884,800.00	76,333
7/19/2016	Sell	12,843	$83.78	$1,075,986.54
6/29/2016	Sell	4,557	$80.00	$364,560.00	76,333
6/20/2016	Sell	7,209	$77.00	$555,093.00	76,333
6/9/2016	Sell	6,910	$74.00	$511,340.00	76,333
6/8/2016	Sell	6,866	$71.00	$487,486.00	76,333
9/1/2015	Sell	8,881	$90.61	$804,707.41	90,000
7/21/2015	Sell	3,786	$83.48	$316,055.28
7/7/2015	Sell	5,000	$79.32	$396,600.00
6/23/2015	Sell	5,154	$77.54	$399,641.16
6/11/2015	Sell	9,869	$73.00	$720,437.00
6/9/2015	Sell	5,000	$70.63	$353,150.00
5/27/2015	Sell	21,791	$69.60	$1,516,653.60
5/18/2015	Sell	15,586	$69.20	$1,078,551.20
5/12/2015	Sell	20,303	$67.84	$1,377,355.52
5/11/2015	Sell	15,303	$68.25	$1,044,429.75
4/28/2015	Sell	10,000	$68.41	$684,100.00
4/27/2015	Sell	5,000	$69.27	$346,350.00
4/14/2015	Sell	20,766	$66.63	$1,383,638.58
2/2/2015	Sell	5,000	$60.69	$303,450.00
1/20/2015	Sell	5,000	$57.58	$287,900.00
1/5/2015	Sell	5,000	$55.27	$276,350.00
8/26/2014	Sell	16,663	$45.30	$754,833.90
3/5/2014	Sell	10,000	$47.30	$473,000.00	187,485
5/15/2013	Sell	5,000	$19.97	$99,850.00

Jeffrey Moy Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $74.46

$74.14

$75.76

50 Day Range

MA: $70.43

$65.68

$76.27

2 Week Range

Now: $74.46

$62.34

$142.00

Volume

3,230,709 shs

Average Volume

3,924,849 shs

Market Capitalization

$29.08 billion

P/E Ratio

44.59

Dividend Yield

N/A

Beta

1.17